Tony Zook has been named to head the U.S. operations of AstraZeneca. Zook has more than 20 years experience and is currently AstraZeneca's senior vice president for U.S. commercial operations.
EPIX Pharmaceuticals has named Michael Astrue, the former president and CEO of Transkaryotic Therapies, as interim CEO.
Christopher H. Price, Ph.D., has resigned as CEO from Nobex to pursue other business opportunities. Dr. Price will serve as a consultant to the company's management team and board of directors. Charles L. Dimmler, III, chairman of the board of Nobex since April 2004, will assume Dr. Price's former responsibilities.
Ambrx has named Martin A Mattingly, Pharm.D., as president and CEO. He was most recently executive vice president and chief operating officer at CancerVax.
Donna Shum has left her post as COO of Wex Pharmaceuticals as a consequence of a corporate restructuring of the company.
The troubled generic drug maker Andrx announced that its CFO, John Hanson, had resigned. No reason was given for the resignation. Andrx recently acknowledged that its plants failed an FDA inspection. Robert I. Goldfarb has been appointed senior vice president, general counsel and secretary.
Glen Sato, senior vice president and CFO of Protein Design Labs, is resigning to join the life sciences practice of a leading law firm. Starting November 2, George Jue, PDL's vice president, finance and chief accounting officer, will oversee the financial organization of PDL.
Genta announced that Richard J. Moran will succeed William Keane as senior vice president and chief financial officer.
Onyx Pharmaceuticals has appointed Henry (Hank) J. Fuchs, M.D., as executive vice president and chief medical officer. Previously Dr. Fuchs was chief executive officer of IntraBiotics, a biotechnology company.
PPD has appointed David Provost to the position of executive director of market development strategic operations.
OncoGenex Technologies has named Cindy Jacobs, Ph.D., M.D., to the position of executive vice president and chief medical officer and the appointment of Monica Krieger, Ph.D., to vice president of regulatory affairs.
Peter Calcott, Ph.D., will join Protein Design Labs as vice president, quality and compliance. Dr. Calcott joins PDL from Chiron Corporation where he served as corporate vice president of quality since 2001.
Par Pharmaceuticals announced that Michael Graves, currently senior vice president, corporate development and strategic planning, has been promoted to the newly created position of president, Generic Products Division. John A. MacPhee, currently senior vice president, branded marketing and sales, has been promoted to the newly created position of president, Branded Products Division.
Roger Marchetti will join Amylin Pharmaceuticals as senior vice president, human resources and corporate services. Marchetti will take over for Martin Brown, who will be retiring from Amylin in October.
Protiveris has named Julian Abery as vice president, business development. Abery held the position of vice president and head of business unit for Biacore A.B.
Emergent BioSolutions has named Allen Shofe to the position of vice president of government affairs. Shofe previously held the position of director of federal government relations at Eli Lilly.
Tranzyme Pharma has named Gordana Kosutic, M.D. as vice president of clinical and regulatory affairs. Prior to joining Tranzyme, Dr. Kosutic served in senior executive positions at Fulcrum Pharma Developments, Nobex Corporation, ClinTrials Research, and ICN Pharmaceuticals.
SyntheMed has named John Hoffer to the newly-created position of director of quality systems and regulatory affairs. Hoffer joins SyntheMed from the Medical Products division of BOC Gases.
Abingworth Management has appointed David Pinniger, CFA as a principal, analyst.
Geoffrey Burnstock, Ph.D., DSc., F.A.A., FMedSci, FRS, has joined CytRx's scientific advisory board.
Dr. Zung Vu Tran will join Bionovo's scientific advisory board.
CoTherix has elected Howard B. Rosen as a member of the company's board of directors.
Stan Hull has joined Palatin's board of directors.
MultiCell Technologies has appointed Anthony Altig to the company's board of directors.
Epitan Limited announced that Dr Wayne Millen, founder of Epitan and former managing director and CEO, will retire as chairman of the board at the company's annual general meeting.
Mylan Laboratories has nominated Neil Dimick to the Mylan board.
Karen A. Dawes has been elected to Repligen's board.